WallStreetZenWallStreetZen

NYSEMKT: LCTX
Lineage Cell Therapeutics Inc Stock Ownership - Who owns Lineage Cell Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Lineage Cell Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Brian M. CulleyPresident and CEO2026-02-1112,869$1.80
$23.16kSell
George A. Samuel IiiGeneral Counsel and Secretary2026-02-112,502$1.80
$4.50kSell
Brian M. CulleyPresident and CEO2025-12-19334$1.68
$561.12Sell
George A. Samuel IiiGeneral Counsel and Secretary2025-12-1965$1.68
$109.20Sell

1 of 1

LCTX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when LCTX insiders and whales buy or sell their stock.

LCTX Shareholders

What type of owners hold Lineage Cell Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Broadwood Partners LP35.40%81,531,259$147.57MInsider
Broadwood Capital Inc21.52%49,560,992$89.71MInstitution
Neal C. Bradsher20.63%47,515,269$86.00MInsider
Alfred D. Kingsley4.49%10,344,637$18.72MInsider
Vanguard Group Inc4.19%9,644,276$17.46MInstitution
Defender Capital LLC2.96%6,829,099$12.36MInstitution
Raffles Associates LP2.33%5,362,788$9.71MInstitution
George Karfunkel2.16%4,982,217$9.02MInsider
Comerica Bank2.00%4,600,000$8.33MInstitution
Blackrock Inc1.66%3,834,113$6.94MInstitution

1 of 3

LCTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
LCTX39.97%60.03%Net SellingNet Selling
RGNX76.14%23.86%Net SellingNet Selling
PRTC0.04%0.00%
RCKT48.96%51.04%Net SellingNet Selling
IMMP0.14%0.00%
View Top Biotech Stocks

Lineage Cell Therapeutics Stock Ownership FAQ

Who owns Lineage Cell Therapeutics?

Lineage Cell Therapeutics (NYSEMKT: LCTX) is owned by 44.14% institutional shareholders, 66.30% Lineage Cell Therapeutics insiders, and 0.00% retail investors. Broadwood Partners LP is the largest individual Lineage Cell Therapeutics shareholder, owning 81.53M shares representing 35.40% of the company. Broadwood Partners LP's Lineage Cell Therapeutics shares are currently valued at $147.57M.

If you're new to stock investing, here's how to buy Lineage Cell Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.